AMAlexander Michels

Alexander Michels

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander Michels has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    NanoPro – a Framework for Probiotically-Guided Nanovector Therapy

    by Alexander Michels, Azra Haseki, Myra Ashraf, Audrey Lam, Kailyn R. Grant, Amy Lu, Rosa L. Vincent, Jongwon Im, Zakary S. Singer, Edward R. Ballister, et al.

    The “antigen problem”, i.e. the disconnect between the broad spectrum of therapeutic modes enabled by the range of viral and synthetic nanoparticles for which workable receptor-targeting architectures exist and the relative dearth of addressable target receptors on most tumors, is a long-standing challenge in targeted tumor nanotherapy. Here we provide in vitro -proof-of-principle for NanoPro, a platform for guiding nanoscale therapeutics to otherwise antigenically indistinct tumors via probiotically-released tumor cell-binding tags, ProTags. These consist of an orthogonal antigen (GFP or ALFA) fused to the heparin-binding domain of placenta growth factor-2 and serve as attachment receptors for ProTag-targeted nanovectors. ProTag release from Escherichia coli Nissle 1917 was facilitated by deletion of the membrane-tethering lpp gene, which increased ProTag supernatant concentrations 16.5–fold compared to the parental strain without impacting viability. HBD-dependent decoration with ProTag in bacterial supernatant followed by treatment with receptor-targeted aGFP- or aALFA-lentiviral vectors resulted in majority transduction of MC-38 and MDA-MB-468 tumor cell lines with antigen specificities of 96.5% and 98.5%, respectively, depending on the choice of nanobody. This ProTag-mediated interaction was notably robust, with selective transduction still observed at 625–fold supernatant dilution, warranting further exploration of the utility of the NanoPro system for tumor-restricted delivery of nanotherapeutics.

  • The emerging landscape of engineered bacteria cancer therapies

    by Edward R. Ballister, Alexander Michels, Rosa L. Vincent, Lior Kreindler, Sreyan Chowdhury, Samik Upadhaya, Ana Rosa Saez-Ibañez, Tao Tu, Juraj Gottweis, Tal Danino